Universität zu Köln

Journal Article

Al-Batran, Salah-Eddin, Hofheinz, Ralf Dieter, Schmalenberg, Harald, Strumberg, Dirk, Goekkurt, Eray, Angermeier, Stefan, Zander, Thomas, Potenberg, Jochem, Kopp, Hans Georg, Pink, Daniel, Siegler, Gabriele Margareta, Schenk, Michael, De Vita, Ferdinando, Maiello, Evaristo, Gaiser, Timo, Sookthai, Disorn, Bankstahl, Ulli Simone, Pauligk, Claudia, Goetze, Thorsten Oliver and Homann, Nils (2020). Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion-A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Chekerov, Radoslav, Hilpert, Felix, Mahner, Sven, El-Balat, Ahmed, Harter, Philipp, De Gregorio, Nikolaus, Fridrich, Claudius, Markmann, Susanne, Potenberg, Jochem, Lorenz, Ralf, Oskay-Oezcelik, Guelten, Schmidt, Marcus ORCID: 0000-0003-1365-2414, Krabisch, Petra, Lueck, Hans-Joachim, Richter, Rolf, Braicu, Elena Ioana, du Bois, Andreas and Sehouli, Jalid (2018). Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 19 (9). S. 1247 - 1259. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Priel, Jan, Hartkopf, Andreas, Potenberg, Jochem, Luedtke-Heckenkamp, Kerstin, Just, Marianne, Wuelfing, Pia, Von Schumann, Raquel, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E., Kreipe, Hans Heinrich and Harbeck, Nadia (2020). De-escalated chemotherapy versus endocrine therapy plus pertuzumab plus trastuzumab for HR+/HER2+early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Nitz, Ulrike, Liedtke, Cornelia, Christgen, Matthias, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Bangemann, Nikola, Lindner, Christoph, Kuemmel, Sherko, Clemens, Michael, Potenberg, Jochem, Staib, Peter, Kohls, Andreas, von Schumann, Raquel and Harbeck, Nadia (2018). Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. JNCI-J. Natl. Cancer Inst., 110 (6). S. 628 - 638. CARY: OXFORD UNIV PRESS INC. ISSN 1460-2105

Graeser, Monika ORCID: 0000-0003-1916-717X, Harbeck, Nadia, Gluz, Oleg, Wuerstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva -Maria, Forstbauer, Helmut, Dimpfl, Moritz ORCID: 0000-0001-6202-7397, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kuemmel, Sherko ORCID: 0000-0001-9355-494X and Nitz, Ulrike (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. Breast, 59. S. 58 - 67. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Graeser, Monika ORCID: 0000-0003-1916-717X, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Herzog, Christopher, Umutlu, Lale, Frydrychowicz, Alex, Rjosk-Dendorfer, Dorothea, Wuerstlein, Rachel, Culemann, Ralph, Eulenburg, Christine, Adams, Jascha, Nitzsche, Henrik, Prange, Anna, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Kolberg-Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K. and Nitz, Ulrike (2021). Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. Breast Cancer Res., 23 (1). LONDON: BMC. ISSN 1465-542X

Graeser, Monika ORCID: 0000-0003-1916-717X, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Wuerstlein, Rachel, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Schumacher, Claudia, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Christgen, Matthias, Adams, Jascha, Nitzsche, Henrik, Just, Marianne, Fischer, Hans Holger, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Potenberg, Jochem, Von Schumann, Raquel, Kolberg-Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K. and Nitz, Ulrike (2021). Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. Int. J. Cancer, 148 (10). S. 2614 - 2628. HOBOKEN: WILEY. ISSN 1097-0215

Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kueemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Nitz, Ulrike Anneliese (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J. Clin. Oncol., 35 (26). S. 3046 - 3057. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Braun, Michael Wilhelm, Kummel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Kleine-Tebbe, Anke, Liedtke, Cornelia, de Haas, Sanne, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg (2018). Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia ORCID: 0000-0002-9744-7372, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers, 13 (19). BASEL: MDPI. ISSN 2072-6694

Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, Zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol., 23 (5). S. 625 - 636. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Nitz, Ulrike A., Gluz, Oleg, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Christgen, Matthias, Braun, Michael, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Luedtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael ORCID: 0000-0001-8539-0148, Kates, Ronald E., Graeser, Monika, Wuerstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H. and Harbeck, Nadia (2022). Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HP2-Early Breast Cancer. J. Clin. Oncol., 40 (23). S. 2557 - 2572. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755